BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35738074)

  • 21. Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
    Dogra S; Elayapillai SP; Qu D; Pitts K; Filatenkov A; Houchen CW; Berry WL; Moxley K; Hannafon BN
    Cancer Lett; 2023 Dec; 578():216437. PubMed ID: 37838282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
    Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
    Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner.
    Razi S; Sadeghi A; Asadi-Lari Z; Tam KJ; Kalantari E; Madjd Z
    Clin Exp Med; 2021 Feb; 21(1):139-147. PubMed ID: 32965580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells.
    Moore LL; Houchen CW
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventive cancer stem cell-based vaccination modulates tumor development in syngeneic colon adenocarcinoma murine model.
    Eini L; Naseri M; Karimi-Busheri F; Bozorgmehr M; Ghods R; Madjd Z
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):4101-4116. PubMed ID: 36040667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of down-regulation of IGF2 gene on the biological characteristics of HCT116 colon cancer stem cells].
    Zhao X; Li J; Liu HQ; Liu XL
    Zhonghua Zhong Liu Za Zhi; 2019 Aug; 41(8):580-586. PubMed ID: 31434448
    [No Abstract]   [Full Text] [Related]  

  • 27. DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axis.
    Kim JH; Park SY; Jeon SE; Choi JH; Lee CJ; Jang TY; Yun HJ; Lee Y; Kim P; Cho SH; Lee JS; Nam JS
    Theranostics; 2022; 12(12):5258-5271. PubMed ID: 35910805
    [No Abstract]   [Full Text] [Related]  

  • 28. DCLK1 inhibition attenuates tumorigenesis and improves chemosensitivity in esophageal squamous cell carcinoma by inhibiting β-catenin/c-Myc signaling.
    Zhang L; Zhou S; Guo E; Chen X; Yang J; Li X
    Pflugers Arch; 2020 Aug; 472(8):1041-1049. PubMed ID: 32533239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chitosan-based nano-formulation enhances the anticancer efficacy of hesperetin.
    Mary Lazer L; Sadhasivam B; Palaniyandi K; Muthuswamy T; Ramachandran I; Balakrishnan A; Pathak S; Narayan S; Ramalingam S
    Int J Biol Macromol; 2018 Feb; 107(Pt B):1988-1998. PubMed ID: 29032208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
    Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
    Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells.
    Liu H; Wen T; Zhou Y; Fan X; Du T; Gao T; Li L; Liu J; Yang L; Yao J; Ge Y; An G
    Biomed Res Int; 2019; 2019():1061979. PubMed ID: 31223610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas.
    Shafiei S; Kalantari E; Saeednejad Zanjani L; Abolhasani M; Asadi Lari MH; Madjd Z
    Exp Mol Pathol; 2019 Jun; 108():164-172. PubMed ID: 31028726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel double-targeted nondrug delivery system for targeting cancer stem cells.
    Qiao S; Zhao Y; Geng S; Li Y; Hou X; Liu Y; Lin FH; Yao L; Tian W
    Int J Nanomedicine; 2016; 11():6667-6678. PubMed ID: 27994463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer.
    Chen Y; Meng L; Wang W; Ye L; Huang L; Wang C; Wang S; Li M; Pei Y; Zhang S; Zou Y; Xu Y
    Eur J Med Chem; 2023 Dec; 261():115846. PubMed ID: 37862816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repurposing diacerein to suppress colorectal cancer growth by inhibiting the DCLK1/STAT3 signaling pathway.
    Ye Q; Zhu Y; Shi M; Lv L; Gong Y; Zhang L; Yang L; Zhao H; Zhao C; Xu H
    Chin J Nat Med; 2024 Apr; 22(4):318-328. PubMed ID: 38658095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.
    Ali N; Chandrakesan P; Nguyen CB; Husain S; Gillaspy AF; Huycke M; Berry WL; May R; Qu D; Weygant N; Sureban SM; Bronze MS; Dhanasekaran DN; Houchen CW
    Oncotarget; 2015 Aug; 6(24):20327-44. PubMed ID: 25948779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c.
    Mohammadi Y; Tavangar SM; Saidijam M; Amini R; Etemadi K; Karimi Dermani F; Najafi R
    Biomed Pharmacother; 2018 Jul; 103():301-307. PubMed ID: 29656186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doublecortin-like kinase 1 is a therapeutic target in squamous cell carcinoma.
    Standing D; Arnold L; Dandawate P; Ottemann B; Snyder V; Ponnurangam S; Sayed A; Subramaniam D; Srinivasan P; Choudhury S; New J; Kwatra D; Ramamoorthy P; Roy BC; Shadoin M; Al-Rajabi R; O'Neil M; Gunewardena S; Ashcraft J; Umar S; Weir SJ; Tawfik O; Padhye SB; Biersack B; Anant S; Thomas SM
    Mol Carcinog; 2023 Feb; 62(2):145-159. PubMed ID: 36218231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of doublecortin-like kinase 1 inhibitors and their bioactivity evaluation.
    Pan P; Ji D; Li Z; Meng X
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2287990. PubMed ID: 38062554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells.
    Carli ALE; Afshar-Sterle S; Rai A; Fang H; O'Keefe R; Tse J; Ferguson FM; Gray NS; Ernst M; Greening DW; Buchert M
    Proteomics; 2021 Jul; 21(13-14):e2000098. PubMed ID: 33991177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.